Medical Oncologist
HER2-positive breast cancer
Neratinib as extended adjuvant HER2 therapy
Neratinib is a daily HER2-targeted tablet that can be offered for a year after trastuzumab-based treatment, mainly for HER2-positive, hormone receptor positive cancers, to lower recurrence risk further. This page explains, in general terms, who it is considered for, how loose motions are managed and how to weigh the benefit.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- What is neratinib and who is it for?
- Stopping after trastuzumab or adding neratinib
- What taking neratinib usually involves
- How a course of neratinib usually runs
- The vocabulary, in plain language
- Weighing the benefit honestly
- Practical tips for managing loose motions
- Questions to ask before starting neratinib
- How neratinib is used when cancer has spread
- What people assume about neratinib
- Common questions about neratinib
The short answer
What is neratinib and who is it for?
Neratinib is a HER2-targeted tablet taken once a day. In early breast cancer it can be offered for a year after completing trastuzumab-based treatment, mainly to women whose cancer is both HER2-positive and hormone receptor positive, to lower the chance of the cancer returning further. This is called extended adjuvant therapy. It is also used in some cases of metastatic HER2-positive breast cancer.
How it differs from trastuzumab
Trastuzumab is an antibody that acts on the outside of cancer cells. Neratinib is a small molecule that works inside the cell, blocking HER2 and related proteins in a different way.
Who tends to benefit most
Studies suggest the benefit is greatest in women whose cancer was hormone receptor positive and who started neratinib soon after finishing trastuzumab. Higher-risk features, such as lymph node involvement, also favour it.
Who it may not suit
Women with hormone receptor negative cancer, those who had a complete response to treatment before surgery, people with significant bowel or liver problems, and those for whom loose motions would be especially difficult to manage.
This page gives general information only. Whether neratinib is right for you is a decision for your oncologist.Side by side
Stopping after trastuzumab or adding neratinib
Stopping after a year of trastuzumab
Adding a year of neratinib
HER2 treatment ends
HER2 treatment continues as tablets
No further HER2 side effects
Loose motions common, especially early
Hormone therapy continues if needed
Hormone therapy continues alongside
No extra cost
Considerable added cost
Standard for most women
Considered for selected higher-risk women
Side effects
What taking neratinib usually involves
Loose motions are the side effect that shapes everything else about neratinib.
Loose motions
Very common, especially in the first weeks. Preventive anti-diarrhoea medicine from the first dose, or starting at a lower dose and building up, greatly reduces the problem.
Feeling sick and stomach pain
Some people feel sick or have cramps. Taking tablets with food and using medicines your team recommends can help.
Take tablets at the same time each day.Tiredness
Often linked to loose motions and dehydration. Drinking enough fluids makes a difference.
Liver changes
Liver blood tests are checked regularly, especially early in treatment.
Call your team if
- Loose motions continue despite medicine
- You feel dizzy or very thirsty
- Your skin or eyes turn yellow
Taking it
How a course of neratinib usually runs
Starting soon after trastuzumab
Neratinib is usually started within a short time of finishing trastuzumab, when the benefit is greatest.
Preventing loose motions from day one
Your team may prescribe anti-diarrhoea medicine to take regularly from the first dose, or start you on a lower dose and build up.
Once a day with food
Tablets are taken daily with a meal, at about the same time each day.
Regular reviews and blood tests
Reviews are more frequent early on to manage side effects and check liver tests.
Continuing for a year
The planned course is usually a year. Dose adjustments are common and help people complete it.
Words you will hear
The vocabulary, in plain language
- Neratinib
- A HER2-targeted tablet that works inside cancer cells.
- Tyrosine kinase inhibitor
- A type of drug that blocks growth signals inside cells.
- Extended adjuvant therapy
- Further treatment after the standard course, to lower recurrence risk more.
- Dose escalation
- Starting at a lower dose and increasing gradually to reduce side effects.
- Preventive anti-diarrhoea medicine
- Medicine taken regularly from the first dose to stop loose motions before they start.
- Hormone receptor positive
- A cancer that grows in response to hormones.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Weighing the benefit honestly
Neratinib lowers the chance of recurrence further for selected women, but the added benefit is modest for many, and the side effects are significant. It is a genuine choice, not an automatic next step.
The benefit depends on your cancer
Studies showed the clearest benefit in hormone receptor positive cancers and in women who started neratinib promptly after trastuzumab. For others, the gain may be very small.
Newer treatments have changed the picture
Neratinib was studied before pertuzumab and T-DM1 were widely used. For women who have already had these, the added benefit is less certain.
Side effects affect daily life
Even with preventive medicines, loose motions can affect work, travel and social life, particularly in the first weeks.
What this page cannot tell you
It cannot tell you whether neratinib would add enough benefit for you. Ask your oncologist for an honest estimate.
Living with it
Practical tips for managing loose motions
Most people who complete neratinib do so because loose motions were managed well from the start. A little planning helps.
Take preventive medicine as prescribed
Do not wait for loose motions to begin. Take the medicine exactly as your team advises, particularly in the early weeks.
Eat and drink with care
Drink plenty of fluids, including oral rehydration solution if advised. Smaller, bland meals and fewer spicy, oily or very high-fibre foods often help.
Plan your days
In the first weeks, know where toilets are when you go out and keep spare clothing handy. This usually becomes easier as your body adjusts.
Making the decision
Questions to ask before starting neratinib
Because the benefit and side effects both matter, a clear conversation helps you decide.
About the benefit
Ask how much neratinib is likely to lower your chance of recurrence, given your receptor status, lymph node results and previous treatments.
About daily life
Ask how loose motions will be prevented, how often you will need reviews, and whether your work or travel plans may be affected.
About cost and alternatives
Ask what it would cost for the full year, whether support is available, and what the plan would be without it.
In metastatic disease
How neratinib is used when cancer has spread
In metastatic HER2-positive breast cancer, neratinib is sometimes used in combination with chemotherapy, usually after other HER2 treatments have been tried. The goals there are to control the cancer and ease symptoms for as long as possible.
Brain metastases
Small molecule tablets like neratinib can reach the brain more easily than antibodies. This is one reason HER2 tablets are considered when cancer has spread to the brain, alongside radiation or surgery.
Managing side effects over time
In metastatic disease treatment may continue for longer, so steady control of loose motions, regular reviews and honest discussion of how you are coping become even more important.
Choosing between options
Several HER2 treatments exist for metastatic disease. Your oncologist will explain where neratinib fits among them for you.
Commonly believed
What people assume about neratinib
Everyone should take neratinib after trastuzumab.
It is considered for selected women, mainly with hormone receptor positive, higher-risk cancers. Many women finish HER2 treatment after trastuzumab without it.
Loose motions mean I have to stop.
Preventive medicines and dose adjustments usually bring loose motions under control. Tell your team early rather than stopping.
Tablets must be milder than infusions.
Neratinib is a strong treatment with significant side effects. Taking it at home does not make it gentle.
If I start late, it will still work just as well.
Studies suggest the benefit is greatest when started soon after trastuzumab. Discuss timing with your oncologist early.
Questions we are asked
Common questions about neratinib
How long do I take neratinib?
In early breast cancer, usually for a year after finishing trastuzumab-based treatment. Your oncologist may adjust the dose along the way to help you complete it.
Can I take it with hormone therapy?
Yes. For hormone receptor positive cancers, hormone therapy usually continues alongside neratinib.
What if I miss a dose?
Do not take an extra dose. Take the next one at the usual time and tell your team at your next review.
Are there foods or medicines to avoid?
Some medicines, including certain antacids and acid-reducing tablets, affect neratinib. Grapefruit may also interact. Give your team a full list of what you take.
Will I lose my hair?
Hair loss is not a typical side effect of neratinib.
Is it safe during pregnancy?
No. Effective contraception is needed during treatment and for a period afterwards. Ask your team how long.
Is neratinib used in metastatic disease?
Yes, in some situations, often combined with other treatment. The goals there differ from early breast cancer.
Where can I read about this drug?
Your oncology team will give you written information about neratinib, including side effects and what to report. Use that as your main reference.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Cancer Research UK — Neratinib (Nerlynx)
- National Cancer Institute — Neratinib maleate
- The Lancet Oncology — Neratinib after trastuzumab-based adjuvant therapy (ExteNET)
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.